Javier Araiza Santibáñez

Dr. Javier Araiza Santibáñez


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2020 in Mycoses
Verified
Journal Article
Closed access
PDF file
ABAlexandro Bonifaz
Alexandro Bonifaz
ATAndrés Tirado-Sánchez
Andrés Tirado-Sánchez
MHMaría L. Hernández‐Medel
María L. Hernández‐Medel
Javier Araiza SantibáñezJavier Araiza Santibáñez
Javier Araiza Santibáñez
JKJuan J. Kassack
Juan J. Kassack
GGGloria M. González
Gloria M. González

22 November 2020 in Australasian Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
ABAlexandro Bonifaz
Alexandro Bonifaz
ATAndrés Tirado-Sánchez
Andrés Tirado-Sánchez
MHMaría L. Hernández‐Medel
María L. Hernández‐Medel
JKJuan J. Kassack
Juan J. Kassack
Javier Araiza SantibáñezJavier Araiza Santibáñez
Javier Araiza Santibáñez
GGGloria M. González
Gloria M. González

9 May 2018 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
ABAlexandro Bonifaz
Alexandro Bonifaz
CTConchita Toriello
Conchita Toriello
Javier Araiza SantibáñezJavier Araiza Santibáñez
Javier Araiza Santibáñez
Max Carlos Ramírez-SotoMax Carlos Ramírez-Soto
Max Carlos Ramírez-Soto
ATAndrés Tirado-Sánchez
Andrés Tirado-Sánchez
Sporotrichosis is the most common implantation mycosis caused by several species of the Sporothrix schenckii complex. The gold standard for diagnosis is concerned with the isolation of the fungus; although, fresh examinations, staining, and biopsies are also helpful for this purpose. The sporotrichin is an antigenic complex comprised of a peptide-rhamnomannan, which is relevant with respect to pathogenic fungi; it is primarily used for serological and skin testing. We present a study regarding the use of sporotrichin as a diagnostic aid for cutaneous sporotrichosis. Furthermore, 138 cases with suspicion of sporotrichosis were included, 55 of which were proven through cultures. Moreover, out of these 55 cases, 52 (94.5%) tested positive for sporotrichin, while the negative cases corresponded to the disseminated cutaneous forms. We observed a sensitivity of 94.5% and a specificity of 95.2%. We consider that the use of sporotrichin as a skin test helps us as an auxiliary diagnosis before a positive sample culture.

31 October 2023 in Mycoses
Verified
Journal Article
Closed access
AGAna Elena Guerrero‐Ponce
Ana Elena Guerrero‐Ponce
Javier Araiza SantibáñezJavier Araiza Santibáñez
Javier Araiza Santibáñez
ATAndrés Tirado-Sánchez
Andrés Tirado-Sánchez
ABAlexandro Bonifaz
Alexandro Bonifaz

28 June 2024 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ACArlen Cruz-Quezada
Arlen Cruz-Quezada
JMJoaquín Moreno
Joaquín Moreno
MSMiguel Ángel Solís-Bravo
Miguel Ángel Solís-Bravo
CCClaudia Andrea López Chávez
Claudia Andrea López Chávez
TSTiburcio Santos
Tiburcio Santos
ABAlexandro Bonifaz
Alexandro Bonifaz
Hemophagocytic lymphohistiocytosis (HLH) is considered a rare disease with high morbidity and mortality risks. Most research on this disease is conducted in pediatric settings. Therefore, this study aimed to describe the clinical characteristics, laboratory findings, and outcomes related to HLH in people living with human immunodeficiency virus (HIV)/AIDS) and disseminated histoplasmosis. A retrospective and descriptive study was conducted in a tertiary hospital in México City from January 2018 to December 2022, including people living with HIV who had disseminated histoplasmosis confirmed through direct microbiological or immunological methods with an HScore ≥169 or who met 5 of the 8 HLH-2004 criteria. HLH occurred in 36.1% (n = 26) of patients with HIV and disseminated histoplasmosis; the majority were men (84.9%), and their mean age (standard deviation) was 30.19 (5.6) years. The most frequent clinical manifestations were hepatomegaly (100%), fever (96.2%), and dyspnea (84.6%). The most common biochemical changes were hyperferritinemia (100%), elevated lactate dehydrogenase (100%), and bicytopenia (61.5%). Partial thromboplastin time (P = .012) and prothrombin time (P = .004) were associated with the 30-day mortality rate, and the 30-day survival rate was 65.4%. We detected a high frequency of HLH; therefore, we encourage physicians to use diagnostic prediction tools (HLH-2004 and HScore criteria) in each reassessment for timely detection.

31 August 2023 in Biomédica
Verified
Journal Article
Open access
PDF file
Javier Araiza SantibáñezJavier Araiza Santibáñez
Javier Araiza Santibáñez
VSValentín Sánchez-Pedraza
Valentín Sánchez-Pedraza
ACAna Karen Carrillo
Ana Karen Carrillo
DFDenise Fernández-Samar
Denise Fernández-Samar
JTJazmín Tejeda
Jazmín Tejeda
ABAlexandro Bonifaz
Alexandro Bonifaz
Introducción. Los pacientes con diabetes mellitus de tipo 2 son propensos a adquirir infecciones por Candida spp., en ocasiones, causadas por más de una especie. La resistencia de algunas de ellas puede resultar en complicaciones médicas por falla del tratamiento.Objetivos. Determinar la frecuencia y las variedades clínicas de la candidiasis oral mixta en pacientes con diabetes mellitus de tipo 2, las especies de Candida involucradas y sus espectros de sensibilidad a los antifúngicos utilizados como tratamiento.Material y métodos. Se hizo un estudio transversal analítico en pacientes con diabetes mellitus de tipo 2, hiperglucemia (superior o igual al 7 % de la hemoglobina glucosilada, HbA1C) y con diagnóstico clínico de candidiasis oral. Mediante técnicas microbiológicas, se identificaron las especies causales de la candidiasis oral. Las pruebas de sensibilidad se llevaron a cabo con el método de difusión en placa con tiras (E-test®).Resultados. Se incluyeron 72 pacientes: 32 (44 %) hombres y 40 (56 %) mujeres, clasificados en tres grupos de edad: jóvenes adultos (17 %), adultos (74 %) y ancianos (9 %), con una media de 51 años. No se encontraron diferencias significativas en la candidiasis oral según los grupos de sexo y edad, ni entre las candidiasis orales mixtas y el sexo, el porcentaje de HbA1C, el tratamiento antihiperglucemiante o el tiempo de diagnóstico de la diabetes mellitus de tipo 2. En el grupo etario de adultos, se encontró una correlación con las candidiasis mixtas o simples. Se encontraron 8 (13 %) casos de candidiasis mixtas: siete con coinfección por dos especies de Candida y uno con coinfección por tres especies. Las especies identificadas en ellos, fueron: Candida albicans, C. glabrata, C. dubliniensis, C. kefyr, C. tropicalis y C. krusei. La mayoría de estas especies presentó sensibilidad a ketoconazol y fluconazol, y mayor resistencia a itraconazol.Conclusiones. Las candidiasis orales mixtas se presentan, aproximadamente, en el 10 % de los pacientes con diabetes mellitus de tipo 2 y el tratamiento puede ser ineficaz cuando no se identifica el agente etiológico.